Deregulation of TGF-β1 has been proposed for multiple neurological disorders including AIDS dementia complex, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), MS, anxiety, depression, and schizophrenia (Kashima and Hata, 2018). This evidence concerns the gene TGFB1 and major depressive disorder.